Type 2 diabetes mellitus. Type 2 diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention group: Patients with Type 2 diabetes mellitus and acute coronary syndrome receiving ß-caryophyllene 150 mg once daily for two months along with standard treatment. Both th
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with type 2 diabetes with a history of acute coronary syndrome according to American College of Heart Disease criteria within the last three months Patients with fasting serum glucose levels greater than or equal to 125 mg/dlPatients with glycosylated hemoglobin blood levels greater than or equal to 6.5% Both male and female gender At least 6 months have passed since the diagnosis of diabetes Age more than 18 years old Consent to admission to the study
Exclusion criteria
Exclusion criteria: Pregnancy Breastfeeding Renal failure and GFR<30 Severe liver failure with liver enzymes three times more than normal Chronic inflammatory disease such as lupus
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hs-CRP serum level. Timepoint: Before the start of the intervention and 8 weeks after the start of the intervention. Method of measurement: ELISA reader device. | — |
Secondary
| Measure | Time frame |
|---|---|
| Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) level. Timepoint: Before the start of the intervention and 8 weeks after the start of the intervention. Method of measurement: Based on the formula for Homeostatic Model Assessment for Insulin Resistance, which is equal to the glucose concentration in millimolar x the insulin concentration in milliinternational units per milliliter (mIU/mL) divided by 22.5.;Triglycerides level. Timepoint: Before the start of the intervention and 8 weeks after the start of the intervention. Method of measurement: Autoanalyzer device.;Insulin level. Timepoint: Before the start of the intervention and 8 weeks after the start of the intervention. Method of measurement: ELISA reader device.;Fasting blood sugar level. Timepoint: Before the start of the intervention and 8 weeks after the start of the intervention. Method of measurement: Autoanalyzer device.;Hemoglobin A1c levels. Timepoint: Before the start of the intervention and 8 weeks after the start of the intervention. Method of measurement: Autoanalyzer with immunoassay method.;Urea level. Timepoint: Before the start of the intervention and 8 weeks after the start of the intervention. Method of measurement: Autoanalyzer device.;Creatinine level. Timepoint: Before the start of the intervention and 8 weeks after the start of the intervention. Method of measurement: Autoanalyzer device.;Alanine aminotransferase (ALT) level. Timepoint: Before the start of the intervention and 8 weeks after the start of the intervention. Method of measurement: Autoanalyzer device.;Aspartate aminotransferase (AST) level. Timepoint: Before the start of the intervention and 8 weeks after the start of the intervention. Method of measurement: Autoanalyzer device.;Interleukin-6 (IL-6) level. Timepoint: Before the start of the intervention and 8 weeks after the start of the intervention. Method of measurement: ELISA reader device.;Low-density lipoprotein (LDL) level. Timepoint: Before the start of th | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Vahid Reza Askari
Mashhad University of Medical Sciences
Outcome results
None listed